Lilly
Executive Summary
Licenses Cytogen's proprietary monoclonal antibody-based technology for the site-specific delivery of vinca alkaloid compounds and other cancer therapies patented by Lilly in return for an unspecified licensing fee, an equity investment and royalty payments. Lilly will be responsible for clinicals and seeking FDA approval. Firms have completed animal testing of possible product formulations. Agreement will complement monoclonal antibody research activities at Lilly's Hybritech subsidiary.
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: